Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study Comparing Concise Versus Prolonged Afatinib as Adjuvant Therapy for Patients With Resected Stage I-III NSCLC With EGFR Mutation

NCT01746251 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT01746251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01746251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study Comparing Concise Versus Prolonged Afatinib as Adjuvant Therapy for Patients With Resected Stage I-III NSCLC With EGFR Mutation
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
January 31, 2013
Completion date
November 30, 2021
Enrollment
92 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer